Scholar Rock Holding Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SRRK research report →
Companyscholarrock.com
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis.
- CEO
- David L. Hallal
- IPO
- 2018
- Employees
- 128
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $5.80B
- P/E
- -15.07
- P/S
- 0.00
- P/B
- 22.31
- EV/EBITDA
- -13.97
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -163.52%
- ROIC
- -85.03%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-377,939,000 · -53.45%
- EPS
- $-3.29 · -33.20%
- Op Income
- $-384,645,000
- FCF YoY
- -49.54%
Performance & Tape
- 52W High
- $51.63
- 52W Low
- $27.07
- 50D MA
- $46.70
- 200D MA
- $40.71
- Beta
- 0.71
- Avg Volume
- 1.51M
Get TickerSpark's AI analysis on SRRK
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 23, 26 | Burow Kristina | other | 18,000 |
| Apr 23, 26 | Burow Kristina | other | 36,000 |
| Apr 23, 26 | Burow Kristina | other | 28,000 |
| Apr 23, 26 | Burow Kristina | other | 7,800 |
| Apr 23, 26 | Burow Kristina | other | 18,000 |
| Apr 23, 26 | Burow Kristina | other | 7,800 |
| Apr 23, 26 | Burow Kristina | other | 28,000 |
| Apr 23, 26 | Burow Kristina | other | 36,000 |
| Apr 16, 26 | Woods Keith | sell | 10,220 |
| Apr 16, 26 | Vaishnaw Akshay | sell | 12,246 |
Our SRRK Coverage
We haven't published any research on SRRK yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SRRK Report →